Overview
QNCX market data
Price History
QNCX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$16.76 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.10 – $910.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $18 · P/B 2.73.
Company News
Quince Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $82 price target.Benzinga · Jul 29, 2026, 5:52 PM
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82Benzinga · Jul 29, 2026, 4:23 PM
8-K/A filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Jun 26, 2026, 8:31 PM
8-K filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Jun 26, 2026, 1:18 PM
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4Benzinga · Jun 24, 2026, 6:50 PM
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4Benzinga · Jun 23, 2026, 4:15 PM
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineBenzinga · May 18, 2026, 2:15 PM
Quince Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -17.39%Benzinga · May 18, 2026, 1:40 PM
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187MBenzinga · May 18, 2026, 1:35 PM
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028Benzinga · May 18, 2026, 1:35 PM